BMEA
Biomea Fusion, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.85
−2.59%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.91
From 52W high−61.70%
Volume1.43M
Market cap$61.35M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.91
From 52W high
−61.70%
Volume
1.43M
Market cap
$61.35M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
28.0
MomentumView details →
1D Return
−2.59%
YTD Return
−30.30%
SummaryUpdated Jun 1, 2026
Biomea Fusion, Inc. (NASDAQ:BMEA) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Redwood City, California. The company went public in April 2021 and focuses on developing innovative covalent small molecule drugs designed to treat patients with genetically defined cancers and metabolic diseases. Biomea Fusion represents part of the new generation of precision medicine companies that aim to target specific genetic mutations responsible for various diseases, particularly in oncology.
Similar companies
Latest newsMore news →
Biomea Fusion, Inc. announced that it will host a conference call and webcast on October 13, 2026, to announce Phase I results for BMF-650.7d agoBiomea Fusion terminated its proposed public offering of securities, announced a day earlier, with no securities sold.27d agoBiomea Fusion, Inc. commenced an underwritten public offering of shares of its common stock and pre-funded warrants to purchase common stock.27d ago